Works matching IS 17762596 AND DT 2024 AND VI 19 AND IP 4

Results: 15
    1
    2
    3
    4

    C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.

    Published in:
    Targeted Oncology, 2024, v. 19, n. 4, p. 635, doi. 10.1007/s11523-024-01068-7
    By:
    • Uchimoto, Taizo;
    • Matsuda, Takuya;
    • Komura, Kazumasa;
    • Fukuokaya, Wataru;
    • Adachi, Takahiro;
    • Hirasawa, Yosuke;
    • Hashimoto, Takeshi;
    • Yoshizawa, Atsuhiko;
    • Saruta, Masanobu;
    • Hashimoto, Mamoru;
    • Higashio, Takuya;
    • Tsuchida, Shuya;
    • Nishimura, Kazuki;
    • Tsujino, Takuya;
    • Nakamura, Ko;
    • Fukushima, Tatsuo;
    • Nishio, Kyosuke;
    • Yamamoto, Shutaro;
    • Iwatani, Kosuke;
    • Urabe, Fumihiko
    Publication type:
    Article
    5

    Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma.

    Published in:
    Targeted Oncology, 2024, v. 19, n. 4, p. 623, doi. 10.1007/s11523-024-01069-6
    By:
    • Yoshino, Maki;
    • Ishihara, Hiroki;
    • Nemoto, Yuki;
    • Mizoguchi, Shinsuke;
    • Ikeda, Takashi;
    • Nakayama, Takayuki;
    • Fukuda, Hironori;
    • Yoshida, Kazuhiko;
    • Iizuka, Junpei;
    • Shimmura, Hiroaki;
    • Hashimoto, Yasunobu;
    • Kondo, Tsunenori;
    • Takagi, Toshio
    Publication type:
    Article
    6
    7
    8
    9

    Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).

    Published in:
    Targeted Oncology, 2024, v. 19, n. 4, p. 587, doi. 10.1007/s11523-024-01065-w
    By:
    • Fiala, Ondřej;
    • Buti, Sebastiano;
    • Bamias, Aristotelis;
    • Massari, Francesco;
    • Pichler, Renate;
    • Maruzzo, Marco;
    • Grande, Enrique;
    • De Giorgi, Ugo;
    • Molina-Cerrillo, Javier;
    • Seront, Emmanuel;
    • Calabrò, Fabio;
    • Myint, Zin W.;
    • Facchini, Gaetano;
    • Kopp, Ray Manneh;
    • Berardi, Rossana;
    • Kucharz, Jakub;
    • Vitale, Maria Giuseppa;
    • Pinto, Alvaro;
    • Formisano, Luigi;
    • Büttner, Thomas
    Publication type:
    Article
    10
    11
    12
    13
    14

    Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.

    Published in:
    Targeted Oncology, 2024, v. 19, n. 4, p. 645, doi. 10.1007/s11523-024-01061-0
    By:
    • Persano, Mara;
    • Rimini, Margherita;
    • Tada, Toshifumi;
    • Suda, Goki;
    • Shimose, Shigeo;
    • Kudo, Masatoshi;
    • Rossari, Federico;
    • Yoo, Changhoon;
    • Cheon, Jaekyung;
    • Finkelmeier, Fabian;
    • Lim, Ho Yeong;
    • Presa, José;
    • Masi, Gianluca;
    • Bergamo, Francesca;
    • Amadeo, Elisabeth;
    • Vitiello, Francesco;
    • Kumada, Takashi;
    • Sakamoto, Naoya;
    • Iwamoto, Hideki;
    • Aoki, Tomoko
    Publication type:
    Article
    15

    Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group.

    Published in:
    Targeted Oncology, 2024, v. 19, n. 4, p. 565, doi. 10.1007/s11523-024-01062-z
    By:
    • Salgado Fernández, Mercedes;
    • Reboredo López, Margarita;
    • Covela Rúa, Marta;
    • Candamio, Sonia;
    • González-Villarroel, Paula;
    • Sánchez-Cousido, Luis Felipe;
    • Graña, Begoña;
    • Carral-Maseda, Alberto;
    • Cameselle-García, Soledad;
    • Varela Pose, Vanesa;
    • Gallardo-Martín, Maria Elena;
    • Martínez-Lago, Nieves
    Publication type:
    Article